[Transdermal therapy of erectile insufficiency].
The introduction of intracavernosal (i.c.) administration of vasoactive drugs has revolutionized diagnosis and treatment of sexual impotence. This procedure, though, carries some risks and undesired side-effects, such as fibrosis, priapism, hematomas, etc. Thus, at our Centre has been evaluated the possibility of a transdermal (TS), either active or passive, treatment of impotence. In a first trial, double blind crossover, 62 patients have been treated with yohimbine (YOH) as ointment. About 5 mg of the drug were applied at the balanopreputial sulcus, twice daily. In 10 patients YOH was also assayed by HPLC in the blood drawn from the corpora cavernosa after the application of the drug: a rapid adsorption of the drug was demonstrated and a peak value of 58 ng/ml at 25 min. Treatment with YOH was particularly satisfactory in patients with impotence of recent onset and mild degree, that is without major vascular alterations. The active TD drug administration was tested with papaverine delivered with cavernous bodies by a C.T.D.A.S. (Controlled Transdermal Drugs Administration System). Thin layer chromatography has shown the passage of about 10% of patients a relevant amelioration of erectile function was observed.
Canale
D
D
Scuola di Specializzazione in Andrologia e Centro di Andrologia, Università degli Studi di Pisa.
Cilurzo
P
P
Giorgi
P M
PM
Menchini Fabris
G F
GF
D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007478:Iontophoresis; D008297:Male; D010208:Papaverine / Q000008:administration & dosage* / Q000627:therapeutic use; D015016:Yohimbine / Q000008:administration & dosage* / Q000627:therapeutic use
D015016:Yohimbine; D010208:Papaverine
La terapia transdermica dell'insufficienza erettile.